Silence Therapeutics PLC (SLN)

Back to homepage

Company Description

Silence Therapeutics PLC was incorporated on November 18, 1994. The Company with its subsidiaries is engaged in the research and development of novel pharmaceutical products. The Company discovers, develops and delivers novel RNAi therapeutics for the treatment of serious diseases. The Company's RNAi therapeutic platform is comprised of proprietary delivery technologies, potent siRNA sequences and siRNA structural features. Its products include Atu027, currently in a Phase 2a clinical trial; AtuPLEX, for endothelial cells of the vascular system; and among others. The Company has operations in Europe, North America, and Asia-Pacific...